RxDoctor Payments Data

Sarah Balla

Family · Perryopolis, PANPI 1427653765

Payments from drug & device makers

$11,336in general payments, 2019–2025

Across 712 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Pfizer$708
  • GSK$672
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$11,336100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,336 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$10,672
Medicare patients
90
Services billed
266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$82,626
EliquisApixaban102$81,636
JardianceEmpagliflozin60$58,245
FarxigaDapagliflozin Propanediol46$41,837
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$41,491
RybelsusSemaglutide27$34,509
JanuviaSitagliptin Phosphate39$28,603
XareltoRivaroxaban42$26,261
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$17,041
Humalog Kwikpen U-200Insulin Lispro13$16,801
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$16,696
MounjaroTirzepatide14$14,595
Tresiba Flextouch U-200Insulin Degludec14$14,524
KerendiaFinerenone11$11,274
VascepaIcosapent Ethyl22$10,539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,081$117,135102 claims
PfizerEliquis$708$81,636102 claims
Boehringer IngelheimJardiance, Stiolto Respimat$474$66,75471 claims
GSKTrelegy Ellipta, Anoro Ellipta, Shingrix$672$64,003121 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,180$58,87863 claims
MerckJanuvia$233$28,60339 claims
Johnson & JohnsonXarelto$229$26,26142 claims
Lilly USA, LLCMounjaro$1,238$14,59514 claims
BayerKerendia$631$11,27411 claims
AbbVieSynthroid$1,297$1,82437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Perryopolis

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →